The group said the move was spurred by its commitment to evidence-based medicine amid a landscape of conflicting public health information.

A single, once-weekly tablet could change HIV treatment landscape; weight loss drug orforglipron efficacy assessed at all stages of menopause; hemophilia ...

Gray matter volume increased by true acupoint, with increases in specific areas positively correlated with motor recovery ...

Zasocitinib is an investigational, once-daily, highly selective oral tyrosine kinase 2 inhibitor being developed for immune-mediated inflammatory diseases.

Sanofi is stopping the phase 3 MOBILIZE clinical trial evaluating riliprubart in adult patients with chronic inflammatory demyelinating polyneuropathy who are refractory to standard therapies.

The FDA linked 12 severe kidney complications to alli between 2007 and 2023, resulting in 8 hospitalizations and 5 patients requiring dialysis. The Food and Drug Administration (FDA) has updated the ...

Retatrutide beneficial as a monotherapy in adults with T2D inadequately controlled with diet and exercise alone.

A new extended maintenance regimen for Ebglyss has been approved for eligible patients with moderate to severe atopic dermatitis.

A wearable ultrasound patch can provide continuous, real-time information about blood flow in the fetus and umbilical cord, according to a study published online May 26 in Nature Biotechnology. Geonho ...

For more than one drink per occasion, higher consumption was associated with progressively increased risks for breast cancer, cardiovascular disease, and injury. HealthDay News — Two drinks per day is ...

For months at Erlanger, Sentri7 failed to raise alarms, overlooking missing drugs and other “inconsistencies” that “should have been flagged,” the nursing board’s order states.

The over-the-counter softgels are used to relieve pressure, bloating, and fullness by rapidly breaking up gas bubbles in the ...